Manzur-Sandoval D, Valdez-Hernández P, Oseguera-Moguel J

Idioma: Español
Referencias bibliográficas: 17
Paginas: 526-532
Archivo PDF: 434.08 Kb.

RESUMEN

El infarto de miocardio es causa importante de muerte y discapacidad en todo el mundo. Es secundario al desequilibrio entre la relación aporte/consumo de oxígeno miocárdico y tiene características clínicas propias. En este artículo se comunica el caso clínico de un paciente con múltiples factores que generaron un desequilibrio en la relación aporte/consumo de oxígeno del miocardio, además de elevación significativa del segmento ST en el electrocardiograma y marcada elevación de la troponina I. Todos estos cambios revirtieron con el inicio del manejo médico de los factores que contribuyeron a este desequilibrio.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Thygesen K, Alpert JS, White HD. Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. J Am Coll Cardiol 2007;50:2173-2195.

2. Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. Eur Heart J 2007;28:2525-2538.

3. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36(3):959-969.

4. Newby LK, Jesse RL, Babb JD, et al. ACCF 2012 expert consensus document on practical guidelines considerations in the interpretation of troponin elevations: a report of the American College of Cardiology Foundation task force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2012;60:2427-63.

5. Alpert JS, Thygesen KA, White HD, et al. Diagnostic and therapeutic implications of type 2 myocardial infarction: review and commentary. Am J Med 2014;127:105-8.

6. Saaby L, Poulsen TS, Hosbond S, et al. Classification of myocardial infarction: frequency and features of type 2 myocardial infarction. Am J Med 2013;126:789-97.

7. Stein GY, Herscovici G, Korenfeld R, et al. Type-II myocardial infarction--patient characteristics, management and outcomes. PLoS One 2014 Jan 2;9(1):e84285.

8. Baron T, Hambraeus K, Sundström J, Erlinge D, Jernberg T, Lindahl B, TOTAL-AMI study group. Type 2 myocardial infarction in clinical practice. Heart 2015;101:101-106.

9. Javed U, Aftab W, Ambrose JA, et al. Frequency of elevated troponin I and diagnosis of acute myocardial infarction. Am J Cardiol 2009;104:9-13.

10. Van Waes JA, Nathoe HM, de Graaff JC, et al; the CHASE investigators. Myocardial injury after noncardiac surgery and its association with short-term mortality. Circulation 2013;127(23):2264-2271.

11. Cohen MC, Aretz TH. Histological analysis of coronary artery lesions in fatal post-operative myocardial infarction. Cardiovasc Pathol 1999;8:133-139.

12. Gualandro DM, Campos CA, Calderaro D, et al. Coronary plaque rupture in patients with myocardial infarction after noncardiac surgery: frequent and dangerous. Atherosclerosis 2012;222(1):191-195.

13. Babuin L, Vasile VC, Rio Perez JA, et al. Elevated cardiac troponin is an independent risk factor for short- and longterm mortality in medical intensive care unit patients. Crit Care Med 2008;36(3):759-765.

14. Vasile VC, Babuin L, Rio Perez JA, et al. Long-term prognostic significance of elevated cardiac troponin levels in critically ill patients with acute gastrointestinal bleeding. Crit Care Med 2009;37(1):140-147.

15. Vasile VC, Chai HS, Abdeldayem D, Afessa B, Jaffe AS. Elevated cardiac troponin T levels in critically ill patients with sepsis. Am J Med 2013;126:1114-21.

16. De Lemos JA. Increasingly sensitive assays for cardiac troponins: a review. JAMA 2013;309:2262-9.

17. Bonaca MP, Wiviott SD, Braunwald E, et al. American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation Universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction). Circulation 2012;125:577-83.